# Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/trastuzumab-deruxtecan-versus-treatment-of-physician-s-choice-in-patients-with/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Fabrice André,Yeon Hee Park,Sung‐Bae Kim,Toshimi Takano,Seock‐Ah Im,Giuliano Borges,João Paulo da Silveira Nogueira Lima,Sercan Aksoy,Joaquín Gavilá Gregori,Michelino De Laurentiis,Giampaolo Bianchini,Rebecca Roylance,Yasuo Miyoshi,Anne Armstrong,Rajni Sinha,Manuel Ruíz Borrego,Elgene Lim,Johannes Ettl,Rinat Yerushalmi,Flora Zagouri,François P. Duhoux,Tanja Fehm,Dhiraj Gambhire,Jillian Cathcart,Wu Cai,Changan Chu,Anton Egorov,Ian E. Krop |
| Citations | 358 |
| DOI | 10.1016/s0140-6736(23)00725-0 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | http://hdl.handle.net/2078.1/274940 |
| OpenAlex ID | https://openalex.org/W4366529414 |
| PMID | 37086745 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Flora Zagouri](https://scholariq.org/researchers/flora-zagouri/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.